Abstract 27

Aims and Objectives: To identify cognitive dysfunction in any treated patient of panhypopituitarism, to identify the realm of cognitive dysfunction in panhypopituitarism, to correlate the cognitive dysfunction with the duration of illness Methods: Study Design: Cross sectional observational study. Study population: Patients admitted in the hospital with Panhypopituitarism during the period from January 2019 to June 2022. Sample Size 50 nos. Assessment of cognitive function was done using Addenbrokes cognitive examination. Results: The results showed majority of the patients were in higher age group, females were majority in the study population. The diagnosis of the conditions presented by the patients showed majority of them having Pituitary adenoma (36%), followed by Empty Sella syndrome (12%). The duration of illness showed that majority (26%) of the patients had the disease for 2.5 years, followed by 1.5 years (24%) and 6 months (22%). The ACE score before showed low mean score of 81.1 and after the treatment mean score increased to 92.7. The delta score of mean difference between the ACE score before and after showed mean score of 11.6. The range of value of ACE before majority (72%) were between 81 to 86. The range of ACE score after the treatment showed major improvement in the ACE score, as majority were in 89 to 92 (52%) and 93 to 96 (48%). There was definitive cognitive improvement before and after treatment. The association between ACE score before treatment and illness duration showed that the ACE score gets lower when the duration of illness of increases. This inverse relationship was statistically significant. The association between ACE score after treatment and illness duration showed that the ACE score gets lower when the duration of illness of increases. This inverse relationship was statistically significant. The association of Attention/Memory against ACE mean scores before and after treatment was shown to have significantly higher score than rest of the variables. The mean ratio is 0.146 ± 0.06. Majority (53%) of the patients had scores between 0.07 to 0.11, followed by 0.12 to 0.19 (24%) and 12% each having 0.20 to 0.24 and 0.25 to .31 score. The correlation between ACE delta score and duration of illness showed that there was direct positive correlation these two factors. The correlation ‘r’ value is 0.109 or else it can be expressed as 10.9% of the changes seen in the ACE delta score can be attributed to the duration of illness. Conclusion: This study has found a direct relationship between duration of illness and their deteriorating cognitive functions with significant improvement of cognitive function post treatment